BIBR 277
Brand names,
BIBR 277
Analogs
BIBR 277
Brand Names Mixture
BIBR 277
Chemical_Formula
C7H9ClO6P2S
BIBR 277
RX_link
http://www.rxlist.com/cgi/generic2/tiludronate.htm
BIBR 277
fda sheet
BIBR 277
msds (material safety sheet)
BIBR 277
Synthesis Reference
No information avaliable
BIBR 277
Molecular Weight
318.609 g/mol
BIBR 277
Melting Point
No information avaliable
BIBR 277
H2O Solubility
No information avaliable
BIBR 277
State
Solid
BIBR 277
LogP
0.549
BIBR 277
Dosage Forms
Tablets for oral administration containing 240 mg tiludronate disodium
BIBR 277
Indication
For treatment of Paget's disease of bone (osteitis deformans).
BIBR 277
Pharmacology
Tiludronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and clodronate. Tiludronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the tiludronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface.
BIBR 277
Absorption
The mean oral bioavailability in healthy male subjects is 6% after an oral dose equivalent to 400 mg tiludronic acid administered after an overnight fast and 4 hours before a standard breakfast. In single-dose studies, bioavailability was reduced by 90% when an oral dose equivalent to 400 mg tiludronic acid was administered with, or 2 hours after, a standard breakfast compared to the same dose administered after an overnight fast and 4 hours before a standard breakfast.
BIBR 277
side effects and Toxicity
Based on the known action of tiludronate, hypocalcemia is a potential consequence of overdose. In one patient with hypercalcemia of malignancy, intravenous administration of high doses (800 mg/day total dose, 6 mg/kg/day for 2 days) was associated with acute renal failure and death.
BIBR 277
Patient Information
BIBR 277
Organisms Affected
Humans and other mammals